Skip to main content
SpringerLink
Log in

Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The HSD11B1 gene encodes the type 1 isoform of the 11-β-hydroxysteroid dehydrogenase that is responsible for the regeneration of glucocorticoids from hormonally-inactive metabolites into active forms in a tissue-specific manner. Altered activity of the enzyme, and certain genetic variants of the HSD11B1 gene, has been associated with various metabolic morbidities. In this study, our aim was to systematically test the potential role of the HSD11B1’s single nucleotide polymorphisms (SNPs) in polycystic ovary syndrome (PCOS). Nine HSD11B1 SNPs were selected and genotyped using Taqman SNP assays on real-time PCR in a group of PCOS patients (n = 58) and in age-matched healthy controls (n = 64). Genotype-phenotype correlations were determined and haplotype analysis was performed. An in silico prediction for potential transcription factor binding sites was also performed. Of the 5 promoter SNPs, 3 (rs760951; rs4844880; rs3753519) were less frequent in the PCOS group compared to healthy controls. SNPs rs4844880 and rs3753519 were in a complete linkage and the mutant haplotype (AA) was less frequent in the PCOS group. No association between HSD11B1 variants and clinical, pathological findings was observed in patients, but in healthy women the rs4844880 and the AA haplotype were associated with higher levels of homeostasis model assessment of beta cell function. The polymorphic form of the rs4844880 was predicted to bind Pbx-1. Promoter SNPs of the HSD11B1 gene might exert a potential genetic protective role against the development of PCOS, possibly via their beneficial effect on carbohydrate homeostasis due to facilitation of insulin efflux from pancreatic beta-cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM (2004) 11 beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25(5):831–866. doi:10.1210/er.2003-0031

    Article  CAS  PubMed  Google Scholar 

  2. Tannin GM, Agarwal AK, Monder C, New MI, White PC (1991) The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 266(25):16653–16658

    CAS  PubMed  Google Scholar 

  3. Stewart PM, Murry BA, Mason JI (1994) Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 79(2):480–484

    CAS  PubMed  Google Scholar 

  4. Bujalska IJ, Kumar S, Stewart PM (1997) Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 349(9060):1210–1213. doi:10.1016/S0140-6736(96)11222-8

    Article  CAS  PubMed  Google Scholar 

  5. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR (2000) Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141(2):560–563

    CAS  PubMed  Google Scholar 

  6. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549):2166–2170. doi:10.1126/science.1066285

    Article  CAS  PubMed  Google Scholar 

  7. Pereira CD, Azevedo I, Monteiro R, Martins MJ (2012) 11 beta-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab. doi:10.1111/j.1463-1326.2012.01582.x

  8. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR (2005) Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54(3):872–879

    Article  CAS  PubMed  Google Scholar 

  9. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR (2001) Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86(3):1418–1421

    Article  CAS  PubMed  Google Scholar 

  10. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T (2002) Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87(7):3330–3336

    CAS  PubMed  Google Scholar 

  11. Stulnig TM, Waldhausl W (2004) 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia 47(1):1–11. doi:10.1007/s00125-003-1284-4

    Article  CAS  PubMed  Google Scholar 

  12. Cooper MS, Stewart PM (2009) 11 Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus–pituitary–adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 94(12):4645–4654. doi:10.1210/jc.2009-1412

    Article  CAS  PubMed  Google Scholar 

  13. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745–2749. doi:10.1210/jc.2003-032046

    Article  CAS  PubMed  Google Scholar 

  14. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85(7):2434–2438

    CAS  PubMed  Google Scholar 

  15. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F (2011) The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 9:39. doi:10.1186/1477-7827-9-39

    Article  PubMed Central  PubMed  Google Scholar 

  16. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif AGJ, Haseltine FP, Merriam GR (eds) Polycystic ovary syndrome. Blackwell, Boston, pp 337–384

    Google Scholar 

  17. Fr DD, Tarlatzis R (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25

    Article  Google Scholar 

  18. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF (2009) The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456–488. doi:10.1016/j.fertnstert.2008.06.035

    Article  PubMed  Google Scholar 

  19. Hart R, Hickey M, Franks S (2004) Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18(5):671–683. doi:10.1016/j.bpobgyn.2004.05.001

    Article  PubMed  Google Scholar 

  20. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S, Marshall JC (2007) Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 92(2):430–436. doi:10.1210/jc.2006-2002

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Baptiste CG, Battista MC, Trottier A, Baillargeon JP (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122(1–3):42–52. doi:10.1016/j.jsbmb.2009.12.010

    Article  CAS  PubMed  Google Scholar 

  22. Moran L, Teede H (2009) Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 15(4):477–488. doi:10.1093/humupd/dmp008

    Article  CAS  PubMed  Google Scholar 

  23. DeUgarte CM, Bartolucci AA, Azziz R (2005) Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83(5):1454–1460. doi:10.1016/j.fertnstert.2004.11.070

    Article  CAS  PubMed  Google Scholar 

  24. Rodin A, Thakkar H, Taylor N, Clayton R (1994) Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 330(7):460–465. doi:10.1056/NEJM199402173300703

    Article  CAS  PubMed  Google Scholar 

  25. Bruley C, Lyons V, Worsley AG, Wilde MD, Darlington GD, Morton NM, Seckl JR, Chapman KE (2006) A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent. Endocrinology 147(6):2879–2885. doi:10.1210/en.2005-1621

    Article  CAS  PubMed  Google Scholar 

  26. Esteves CL, Verma M, Rog-Zielinska E, Kelly V, Sai S, Breton A, Donadeu FX, Seckl JR, Chapman KE (2013) Pro-inflammatory cytokine induction of 11beta-hydroxysteroid dehydrogenase type 1 in A549 cells requires phosphorylation of C/EBPbeta at Thr235. PLoS ONE 8(9):e75874. doi:10.1371/journal.pone.0075874

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Svendsen PF, Madsbad S, Nilas L, Paulsen SK, Pedersen SB (2009) Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. Int J Obes (Lond) 33(11):1249–1256. doi:10.1038/ijo.2009.165

    Article  CAS  Google Scholar 

  28. Mlinar B, Marc J, Jensterle M, Bokal EV, Jerin A, Pfeifer M (2011) Expression of 11beta-hydroxysteroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with adiposity. J Steroid Biochem Mol Biol 123(3–5):127–132. doi:10.1016/j.jsbmb.2010.12.002

    Article  CAS  PubMed  Google Scholar 

  29. Gambineri A, Tomassoni F, Munarini A, Stimson RH, Mioni R, Pagotto U, Chapman KE, Andrew R, Mantovani V, Pasquali R, Walker BR (2011) A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol 165(2):283–292. doi:10.1530/EJE-11-0091

    Article  CAS  PubMed  Google Scholar 

  30. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM (2003) Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34(4):434–439. doi:10.1038/ng1214

    Article  CAS  PubMed  Google Scholar 

  31. Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, Walker BR (2006) Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 91(6):2295–2302. doi:10.1210/jc.2005-2222

    Article  CAS  PubMed  Google Scholar 

  32. Feldman K, Szappanos A, Butz H, Grolmusz V, Majnik J, Liko I, Kriszt B, Lakatos P, Toth M, Racz K, Patocs A (2012) The rs4844880 polymorphism in the promoter region of the HSD11B1 gene associates with bone mineral density in healthy and postmenopausal osteoporotic women. Steroids 77(13):1345–1351. doi:10.1016/j.steroids.2012.08.014

    Article  CAS  PubMed  Google Scholar 

  33. Chua AK, Azziz R, Goodarzi MO (2012) Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage. Mol Hum Reprod 18(6):320–324. doi:10.1093/molehr/gas002

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Szappanos A, Patocs A, Gergics P, Bertalan R, Kerti A, Acs B, Feldmann K, Racz K, Toth M (2011) The 83,557insA variant of the gene coding 11beta-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing’s syndrome. J Steroid Biochem Mol Biol 123(1–2):79–84. doi:10.1016/j.jsbmb.2010.11.009

    Article  CAS  PubMed  Google Scholar 

  35. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, Podkolodny NL, Kolchanov NA (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26(1):362–367

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Margalit Y, Yarus S, Shapira E, Gruenbaum Y, Fainsod A (1993) Isolation and characterization of target sequences of the chicken CdxA homeobox gene. Nucleic Acids Res 21(21):4915–4922

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Rocha AA, Morais FV, Puccia R (2009) Polymorphism in the flanking regions of the PbGP43 gene from the human pathogen Paracoccidioides brasiliensis: search for protein binding sequences and poly(A) cleavage sites. BMC Microbiol 9:277. doi:10.1186/1471-2180-9-277

    Article  PubMed Central  PubMed  Google Scholar 

  38. Bajic VB, Brent MR, Brown RH, Frankish A, Harrow J, Ohler U, Solovyev VV, Tan SL (2006) Performance assessment of promoter predictions on ENCODE regions in the EGASP experiment. Genome Biol 7(Suppl 1):S3-1-13. doi:10.1186/gb-2006-7-s1-s3

  39. Urbanek M (2007) The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 3(2):103–111. doi:10.1038/ncpendmet0400

    Article  CAS  PubMed  Google Scholar 

  40. Goodarzi MO (2008) Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med 26(1):5–13. doi:10.1055/s-2007-992919

    Article  CAS  PubMed  Google Scholar 

  41. Grolmusz VK, Stenczer B, Fekete T, Szendei G, Patocs A, Racz K, Reismann P (2013) Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 121(6):338–342. doi:10.1055/s-0033-1337941

    Article  CAS  PubMed  Google Scholar 

  42. Valkenburg O, Uitterlinden AG, Themmen AP, de Jong FH, Hofman A, Fauser BC, Laven JS (2011) Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Hum Reprod 26(10):2902–2911. doi:10.1093/humrep/der222

    Article  CAS  PubMed  Google Scholar 

  43. Malavasi EL, Kelly V, Nath N, Gambineri A, Dakin RS, Pagotto U, Pasquali R, Walker BR, Chapman KE (2010) Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels. Endocrinology 151(1):195–202. doi:10.1210/en.2009-0663

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419

    Article  CAS  PubMed  Google Scholar 

  45. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85(7):2402–2410

    Article  CAS  PubMed  Google Scholar 

  46. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM (2008) 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 51(11):2003–2011. doi:10.1007/s00125-008-1137-2

    Article  CAS  PubMed  Google Scholar 

  47. Davani B, Khan A, Hult M, Martensson E, Okret S, Efendic S, Jornvall H, Oppermann UC (2000) Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 275(45):34841–34844. doi:10.1074/jbc.C000600200

    Article  CAS  PubMed  Google Scholar 

  48. Ortsater H, Alberts P, Warpman U, Engblom LO, Abrahmsen L, Bergsten P (2005) Regulation of 11beta-hydroxysteroid dehydrogenase type 1 and glucose-stimulated insulin secretion in pancreatic islets of Langerhans. Diabetes Metab Res Rev 21(4):359–366. doi:10.1002/dmrr.525

    Article  PubMed  Google Scholar 

  49. Tiemann K, Panienka R, Kloppel G (2007) Expression of transcription factors and precursor cell markers during regeneration of beta cells in pancreata of rats treated with streptozotocin. Virchows Arch 450(3):261–266. doi:10.1007/s00428-006-0349-4

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

P.R., A.P. and K.R. designed research, P.R., T.F. and Gy.Sz. evaluated patients, V.K.G., O.D.Á, B.S. and P.R. performed laboratory work, V.K.G., K.F.-K., Á.Sz. and A.P. analyzed data, V.K.G., K.R. and A.P. wrote the paper. All authors—except the late Gy.Sz.—reviewed the paper. The authors acknowledge the financial support from Hungarian Scientific Research Fund (OTKA PD-100648), Hungarian Academy of Sciences “Lendulet 2013” Grant (AP) and National Development Agency (KTIA-AIK-10_2012-0010).

Conflict of interest

All authors have nothing to declare.

Author information

Authors and Affiliations

  1. 2nd Department of Medicine, Semmelweis University, Szentkirályi 46, Budapest, 1088, Hungary

    Vince Kornél Grolmusz, Orsolya Dóra Ács, Karolina Feldman-Kovács, Ágnes Szappanos, Péter Reismann & Károly Rácz

  2. 1st Department of Obstetrics and Gynecology, Semmelweis University, Baross 27, Budapest, 1085, Hungary

    Balázs Stenczer, Tibor Fekete & György Szendei

  3. HAS-SE Molecular Medicine Research Group, Hungarian Academy of Sciences, Szentkirályi 46, Budapest, 1088, Hungary

    Attila Patócs

  4. Department of Laboratory Medicine, Semmelweis University, Nagyvárad 4, Budapest, 1089, Hungary

    Attila Patócs

  5. HAS-SE “Lendulet” Hereditary Endocrine Tumours Research Group, Semmelweis University, 46 Szentkirályi, Budapest, 1088, Hungary

    Attila Patócs

Authors
  1. Vince Kornél Grolmusz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orsolya Dóra Ács
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karolina Feldman-Kovács
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ágnes Szappanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Balázs Stenczer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tibor Fekete
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. György Szendei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Péter Reismann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Károly Rácz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Attila Patócs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Attila Patócs.

Additional information

G. Szendei—deceased.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grolmusz, V.K., Ács, O.D., Feldman-Kovács, K. et al. Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome. Mol Biol Rep 41, 5961–5969 (2014). https://doi.org/10.1007/s11033-014-3473-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3473-2

Keywords

Search

Navigation